Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. [electronic resource]
Producer: 20070911Description: 3892-901 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Boronic Acids -- administration & dosage
- Bortezomib
- Cardiovascular Diseases -- chemically induced
- Disease Progression
- Disease-Free Survival
- Doxorubicin -- administration & dosage
- Drug Resistance, Neoplasm
- Female
- Hematologic Diseases -- chemically induced
- Humans
- Incidence
- Male
- Middle Aged
- Multiple Myeloma -- drug therapy
- Neoplasm Recurrence, Local
- Polyethylene Glycols -- administration & dosage
- Pyrazines -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.